Thymosin Alpha-1

In published clinical research, Thymosin Alpha-1 (Zadaxin®) has been administered at a standard dose of 1.6 mg per administration. This is the dose used across major clinical trials.

Published literature reports twice-weekly subcutaneous administration protocols as the standard in clinical research, with some intensive protocols using daily dosing.

Published literature reports reconstitution of 10 mg vials in 3–5 mL bacteriostatic water, yielding concentrations of 2–3.3 mg/mL. Using 5 mL (2 mg/mL) is standard for the small 1.6 mg clinical dose.

At 2 mg/mL (5 mL water), a standard 1.6 mg research dose equals 80 units (0.8 mL). At 3.3 mg/mL (3 mL water), the same dose equals 48 units (0.48 mL).